Vasopressin antagonists in heart failure.

Ladan Golestaneh; Ashok Talreja; Thierry H. Le Jemtel

doi:10.1007/s11897-004-0008-5

Vasopressin antagonists in heart failure.

Ladan Golestaneh, Ashok Talreja, Thierry H. Le Jemtel

Medicine

Research output: Contribution to journal › Review article › peer-review

5 Scopus citations

Abstract

The recrudescence of interest in manipulation of the arginine vasopressin system and especially of V2 vasopressin receptor blockade in heart failure stems from the limited efficacy and possible detrimental effects of loop diuretics. The "braking phenomenon," hypertrophy of the collecting duct cells, and altered pharmacodynamics contribute to loop diuretic resistance in heart failure. Selective (tolvaptan) and nonselective (conivaptan) V2 vasopressin receptor antagonists now known as "vaptans" promote free-water excretion that is labeled aquaresis and correct hyponatremia in patients with severe heart failure. A large mortality study with tolvaptan in heart failure is presently ongoing.

Original language	English (US)
Pages (from-to)	190-196
Number of pages	7
Journal	Current heart failure reports
Volume	1
Issue number	4
DOIs	https://doi.org/10.1007/s11897-004-0008-5
State	Published - Dec 2004

ASJC Scopus subject areas

Emergency Medicine
Cardiology and Cardiovascular Medicine
Physiology (medical)

Access to Document

10.1007/s11897-004-0008-5

Cite this

@article{8954584a3f9b45218d62997c8282ecbe,

title = "Vasopressin antagonists in heart failure.",

abstract = "The recrudescence of interest in manipulation of the arginine vasopressin system and especially of V2 vasopressin receptor blockade in heart failure stems from the limited efficacy and possible detrimental effects of loop diuretics. The {"}braking phenomenon,{"} hypertrophy of the collecting duct cells, and altered pharmacodynamics contribute to loop diuretic resistance in heart failure. Selective (tolvaptan) and nonselective (conivaptan) V2 vasopressin receptor antagonists now known as {"}vaptans{"} promote free-water excretion that is labeled aquaresis and correct hyponatremia in patients with severe heart failure. A large mortality study with tolvaptan in heart failure is presently ongoing.",

author = "Ladan Golestaneh and Ashok Talreja and {Le Jemtel}, {Thierry H.}",

year = "2004",

month = dec,

doi = "10.1007/s11897-004-0008-5",

language = "English (US)",

volume = "1",

pages = "190--196",

journal = "Current heart failure reports",

issn = "1546-9530",

publisher = "Current Science, Inc.",

number = "4",

}

TY - JOUR

T1 - Vasopressin antagonists in heart failure.

AU - Golestaneh, Ladan

AU - Talreja, Ashok

AU - Le Jemtel, Thierry H.

PY - 2004/12

Y1 - 2004/12

N2 - The recrudescence of interest in manipulation of the arginine vasopressin system and especially of V2 vasopressin receptor blockade in heart failure stems from the limited efficacy and possible detrimental effects of loop diuretics. The "braking phenomenon," hypertrophy of the collecting duct cells, and altered pharmacodynamics contribute to loop diuretic resistance in heart failure. Selective (tolvaptan) and nonselective (conivaptan) V2 vasopressin receptor antagonists now known as "vaptans" promote free-water excretion that is labeled aquaresis and correct hyponatremia in patients with severe heart failure. A large mortality study with tolvaptan in heart failure is presently ongoing.

AB - The recrudescence of interest in manipulation of the arginine vasopressin system and especially of V2 vasopressin receptor blockade in heart failure stems from the limited efficacy and possible detrimental effects of loop diuretics. The "braking phenomenon," hypertrophy of the collecting duct cells, and altered pharmacodynamics contribute to loop diuretic resistance in heart failure. Selective (tolvaptan) and nonselective (conivaptan) V2 vasopressin receptor antagonists now known as "vaptans" promote free-water excretion that is labeled aquaresis and correct hyponatremia in patients with severe heart failure. A large mortality study with tolvaptan in heart failure is presently ongoing.

UR - http://www.scopus.com/inward/record.url?scp=26044458689&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=26044458689&partnerID=8YFLogxK

U2 - 10.1007/s11897-004-0008-5

DO - 10.1007/s11897-004-0008-5

M3 - Review article

C2 - 16036044

AN - SCOPUS:26044458689

SN - 1546-9530

VL - 1

SP - 190

EP - 196

JO - Current heart failure reports

JF - Current heart failure reports

IS - 4

ER -

Vasopressin antagonists in heart failure.

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this